Table. Overview of the 17 Phase 3 Randomized Clinical Trials Included.

Trial	Line	Region	Experimental group(s)	Control group	Patients, No.
					Total	AC	SCC
SCC trials
CM-64810	1	Asia and non-Asia	Anti−PD-1 + chemotherapy	Chemotherapy	970	0	970
			Anti−PD-1 + anti−CTLA-4 (2 arms)
ESCORT-1st12	1	Asia	Anti−PD-1 + chemotherapy	Chemotherapy	596	0	596
ORIENT-1521	1	Asia	Anti−PD-1 + chemotherapy	Chemotherapy	659	0	659
JUPITER-0622	1	Asia	Anti−PD-1 + chemotherapy	Chemotherapy	514	0	514
ATTRACTION-037	2	Asia	Anti−PD-1	Chemotherapy	419	0	419
ESCORT11	2	Asia	Anti−PD-1	Chemotherapy	448	0	448
RATIONALE-30219	2	Asia and non-Asia	Anti−PD-1	Chemotherapy	512	0	512
AC trials
CM-6498,9	1	Asia and non-Asia	Anti−PD-1 + chemotherapy	Chemotherapy	1581	1581	0
KN-06215	1	Asia and non-Asia	Anti−PD-1 + chemotherapy	Chemotherapy	763	763	0
			Anti−PD-1 (2 arms)
ATTRACTION-045	1	Asia	Anti−PD-1 + chemotherapy	Chemotherapy	724	724	0
ORIENT-1620	1	Asia	Anti−PD-1 + chemotherapy	Chemotherapy	650	650	0
JAVELIN-10013	MAINT	Asia and non-Asia	Anti−PD-L1	Chemotherapy	499	499	0
KN-06116	2	Asia and non-Asia	Anti−PD-1	Chemotherapy	590	590	0
ATTRACTION-026	3	Asia	Anti−PD-1	Placebo	493	493	0
JAVELIN-30014	3	Asia and non-Asia	Anti−PD-L1	Chemotherapy	371	371	0
Mixed SCC and AC trials
KN-59018	1	Asia and non-Asia	Anti−PD-1 + chemotherapy	Chemotherapy	749	201	548
KN-18117	2	Asia and non-Asia	Anti−PD-1	Chemotherapy	628	227	401
Total	NA	NA	NA	NA	11 166	6099	5067

Abbreviations: AC, adenocarcinoma; CTLA, cytotoxic T-lymphocyte-associated protein 4; MAINT, maintenance; NA, not applicable; PD-L1, programmed death-ligand 1; SCC, squamous cell carcinoma.